Beyond borders 2009: Insights into the global biotechnology industry - Ernst & Young - France

Beyond borders: global biotechnology report 2009

How has the global financial crisis affected the biotech industry? Beyond borders 2009 presents comprehensive data on the industry’s financial performance in 2008, including financial results, financing, M&As, strategic alliances, product approvals and pipeline growth. Learn how the crisis is impacting leading biotech markets in the US, Europe and Asia-Pacific.

Leading executives offer perspective

Tap into timely advice from a wide range of industry experts. This year’s report showcases:

• Guest articles by the CEOs of Gilead Sciences and Bristol-Myers Squibb
• A roundtable with the CEOs of four next-generation industry leaders on the outlook for the biotech industry and their companies
• Views from 11 leading venture capitalists on the financial crisis
• A roundtable with four business development executives on creative deal-making approaches in the current crisis
• Articles by Adelene Perkins of Infinity Pharmaceuticals and Samantha Du of Hutchison MediPharma on the need for different models
• An article on new approaches for valuing innovation by Andrew Dillon and Sarah Garner of NICE
• An interview with India’s M.K. Bhan on changing realities in the Indian market and the implications of the financial crisis
• An article by Peter Wirth of Genzyme on the interconnected nature of the financial crisis
• A roundtable with executives from three leading European industrial biotech firms

Time for new business models?

Challenging times have always inspired biotech’s creativity. So it’s not surprising that the search for creative models — both to overcome immediate operational challenges in the current environment and to foster the sector’s long-term sustainability — is a core theme in this year’s Beyond borders. We present four paradigm-shifting trends that have the potential to reshape the healthcare landscape and create new opportunities: high-quality generics, fundamental healthcare reform in the US, personalized medicine and globalization.

Request a copy of Beyond borders

Request your copy of Beyond borders 2009 for a comprehensive view of the challenges facing the industry as the business of biotech goes beyond business as usual.